Cellid, BlueMtec Rally on Change-of-Control Deals; Inventera Gains[K-bio pulse]

This article was released as Pharm Edaily Premium Content on September 23, 2026, at 8:35 AM.[Kim Jin Soo, Edaily Repoeter] On Sept. 22, change-of-control developments at biotech companies drew significant attention across South Korea’s pharmaceutical and biotech sector. Vaccine developer Cellid surged after announcing a deal with Huniverse Global, while pharmaceutical distribution and platform company BlueMtec climbed amid reports linking it to Kolmar Group.Inventera also attracted investor interest after reporting significant results from a Phase 3 clinical trial of its investigational magnetic resonance imaging(MRI) contrast agent.Cellid stock trend. (KG zeroin)Cellid Transfers Control, CEO Kang to Remain InvolvedCellid shares hit the daily upper limit in early trading before closing at KRW 2,885, up KRW 665 from the previous session. The rally was attributed to the company’s announcement of a KRW 10 billion third-party allotment capital increase and a planned change in management control.Cellid disclosed on Sept. 21 that it had signed an agreement with Huniverse Global concerning a change in management control through the issuance of new shares.Under the agreement, Cellid will i...